• Philip Morris International Inc. recently announced that its non-U.S. affiliates entered into a contract manufacturing arrangement for combustible cigarettes with Philip Morris USA, an Altria Group company, with initial shipments targeted for early 2027 and no expected material impact on 2026 financials.
• The deal underlines how PMI aims to use its manufacturing scale in combustibles while still emphasizing a transition toward smoke-free products.
• We’ll now examine how this contract manufacturing partnership with Philip Morris USA could influence Philip Morris International’s existing investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Philip Morris International Investment Narrative Recap

To own Philip Morris International, you generally need to believe its smoke free products can grow enough to offset gradual declines in combustibles, while funding attractive shareholder returns from solid cash flows. The new contract manufacturing deal with Philip Morris USA mainly reinforces PMI’s role as an efficient producer of combustibles and, with no material impact expected on 2026 financials, does not significantly shift the near term smoke free growth catalyst or the key risks around regulation and illicit trade.

The most relevant recent announcement here is the FDA’s Marketing Granted Orders and Modified Risk Tobacco Product authorizations for multiple ZYN variants, which strengthen PMI’s smoke free portfolio. That regulatory progress supports the central investment angle that reduced exposure products can increasingly drive revenue and margins, even as cigarette volumes trend lower. The new contract manufacturing agreement sits alongside this by monetizing existing combustible capacity without altering PMI’s focus on smoke free offerings.

Yet behind this progress, tightening regulation and litigation risks, such as the Brazil healthcare cost recovery case, remain issues that investors should be aware of...

Philip Morris International's narrative projects $49.8 billion revenue and $15.5 billion earnings by 2029. This requires 5.4% yearly revenue growth and a $4.7 billion earnings increase from $10.8 billion today.

Uncover how Philip Morris International's forecasts yield a $203.80 fair value, a 6% upside to its current price.

Exploring Other Perspectives

While consensus assumes steady growth, the most pessimistic analysts, who were modeling about US$48.9 billion in revenue and US$15.0 billion in earnings by 2029, see tougher regulation and higher capital needs as real threats, so you should weigh this more cautious view against the new manufacturing deal and consider how future updates could shift both narratives.

Explore 6 other fair value estimates on Philip Morris International - why the stock might be worth as much as 19% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Philip Morris International research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Philip Morris International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Philip Morris International's overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.